In 2021, the National Institute for Health and Care Excellence (NICE) updated its guidance on obstructive sleep apnoea/hypopnoea syndrome (OSAHS), reaffirming that continuous positive airway pressure (PAP) is the first-line treatment for moderate-to-severe disease. The evidence is robust: a meta-analysis of 20 randomised controlled trials found that PAP reduces the apnoea-hypopnoea index (AHI) by roughly 75%, and observational data suggest a 30% drop in cardiovascular mortality among adherent users. Yet for many patients in England, the journey from diagnosis to a functioning machine at home stretches well beyond six months.

Guidelines Say PAP, But the Waitlist Says Otherwise

NICE recommends that adults with moderate-to-severe OSA (AHI ≥15 events per hour) be offered PAP therapy. The guideline is clear, but implementation is patchy. A 2023 survey of 200 sleep centres across the UK reported a median wait of 7.2 months from referral to home setup, with some trusts exceeding eight months. The British Sleep Society has flagged this as a systemic failure, noting that delays of this magnitude expose patients to ongoing cardiovascular strain and debilitating daytime sleepiness.

Untreated OSA is linked to hypertension, stroke, and arrhythmias. A 2022 study in Thorax estimated that each month of delayed treatment increases the odds of a cardiovascular event by roughly 2%. Meanwhile, daytime sleepiness raises the risk of road traffic accidents by two- to three-fold, according to data from the Department for Transport. For a condition that affects an estimated 5–10% of adults—many undiagnosed—the waitlist is not an administrative inconvenience; it is a clinical hazard.

Clinicians on the front line describe a frustrating cycle. Patients referred by GPs often wait 14 months for a diagnostic sleep study, then another 6–8 months for PAP setup. By the time they receive therapy, some have lost faith in the system or developed complications. “We are treating a chronic disease with an acute-care mindset,” one respiratory consultant told the Health Service Journal last year.

Consider the case of a 52-year-old lorry driver from Leeds, referred by his GP in early 2023 after his wife reported loud snoring and observed breathing pauses. He underwent a home sleep study in May 2023, which revealed severe OSA with an AHI of 42 events per hour. But the local sleep centre had a six-month wait for PAP setup. During that time, he continued to experience microsleeps while driving, narrowly avoiding an accident. When he finally received his CPAP machine in December 2023, his Epworth Sleepiness Scale score had dropped from 18 to 6 within a month. Stories like his are not rare; patient forums are filled with accounts of prolonged waits and near-misses.

The Evidence for PAP Is Strong—When Used

The efficacy of PAP in controlled trials is striking. A Cochrane review of 36 RCTs found that CPAP reduces AHI by a mean of 75% compared with sham or no treatment, and improves subjective sleepiness scores by roughly 3 points on the Epworth Sleepiness Scale. In adherent patients—those using the device at least 4 hours per night—cardiovascular mortality appears to drop by about 30% over five years, according to a large Spanish cohort study. Another meta-analysis from 2020, pooling data from over 10,000 patients, reported a hazard ratio of 0.72 for major adverse cardiovascular events among PAP users versus non-users.

But real-world adherence is a different story. UK audit data from 2023 show that average nightly use hovers around 4.5 hours, and the dropout rate at one year exceeds 25%. Some patients struggle with mask discomfort, noise, or claustrophobia; others find the device intrusive. A 2021 trial of telemonitoring-based support found that adherence could be improved by roughly 30 minutes per night, but the effect was modest and faded after six months. A separate study from the US showed that cognitive behavioural therapy for insomnia, when combined with PAP, improved adherence by about 45 minutes per night at three months, but the intervention required specialist input not routinely available in the NHS.

The gap between efficacy and effectiveness is well recognised. “PAP works if you use it, but many patients don’t,” wrote a group of researchers in The Lancet Respiratory Medicine. They called for more investment in behavioural support and device optimisation, rather than simply prescribing and hoping. Yet even when patients are motivated, the wait to start therapy can sap their enthusiasm. A qualitative study from the University of Oxford found that patients who waited more than six months for treatment reported lower motivation and more anxiety about using the device, compared with those who started within two months.

Why Home Setup Bottlenecks Persist

The reasons behind the delays are multiple. First, there is a shortage of trained respiratory physiologists. The NHS has roughly 300 such specialists, but the Royal College of Physicians estimates that at least 500 are needed to meet current demand. Training posts have not kept pace with the rising prevalence of OSA, which itself is driven by increasing obesity rates—roughly 64% of adults in England are now overweight or obese, a key risk factor. The number of sleep studies performed annually has increased by about 40% over the past decade, but the physiologist workforce has grown by less than 10%.

Second, funding caps on CPAP devices vary by clinical commissioning group (CCG). Some CCGs limit the number of machines they will purchase per quarter, creating artificial ceilings. A 2022 Freedom of Information request by the charity Sleep Apnoea UK found that five of 42 CCGs had a waiting list for devices of more than 12 months. The cost of a basic CPAP machine is around £200–400, but the NHS tariff for setup and follow-up can push the total to £600–800 per patient. For a typical CCG serving 500,000 people, the annual budget for sleep services might be around £500,000, which is quickly exhausted when each patient costs £600–800 and hundreds are referred each year.

Third, the referral-to-diagnosis pathway remains cumbersome. Many patients are referred to hospital-based sleep centres that have limited capacity. The COVID-19 pandemic exacerbated this, with diagnostic services paused for months and a backlog that is still being cleared. A 2024 report from the British Thoracic Society noted that the number of sleep studies performed in 2023 was still 15% below pre-pandemic levels. Some trusts have resorted to using single-channel oximetry as a triage tool, but this is less accurate than full polysomnography and can lead to misclassification.

Another factor is the variability in commissioning. In some areas, sleep services are commissioned by the local CCG; in others, by NHS England specialised commissioning. This fragmentation leads to inconsistent pathways and funding. For example, a patient in Birmingham might be offered a home sleep study within four weeks, while a patient in Cornwall might wait 16 weeks for the same test. Postcode lotteries of this kind undermine equity and make it difficult to implement national standards.

A Pilot Scheme in Manchester Cut Wait Times by Half

In response to these challenges, a pilot programme in Manchester tested a community-based model for PAP setup. Instead of requiring patients to attend a hospital for in-lab titration, they were given an auto-CPAP device at home, with remote monitoring via a smartphone app. The device adjusted pressure automatically based on real-time feedback, and a respiratory nurse reviewed the data weekly.

The results were encouraging. Over 18 months, the median wait from referral to treatment dropped from eight months to four. Patient satisfaction scores were high, and the cost per patient fell by roughly 18%, largely because fewer hospital visits were needed. A follow-up audit at 12 months showed that adherence rates were similar to those in the hospital-based pathway, suggesting no loss of effectiveness. The pilot also reduced the burden on hospital sleep laboratories, freeing up capacity for complex diagnostic cases.

“This model shows that we can deliver care closer to home without compromising outcomes,” said the lead investigator, Dr. Sarah Jenkins, at a 2024 sleep conference. The pilot has since been expanded to two neighbouring trusts, and NHS England is evaluating whether to adopt it more widely. However, scaling up will require investment in remote monitoring platforms and community nursing teams—resources that are currently stretched. A health economics analysis from the pilot estimated a net saving of £120 per patient over two years, but the upfront cost of purchasing auto-CPAP devices and training community nurses was around £50,000 per trust.

Critics of the community model point out that not all patients are suitable for auto-CPAP. Those with complex comorbidities—such as central sleep apnoea or severe obesity hypoventilation—may still need in-lab titration. However, the pilot excluded such patients, and the success rate among the included group was high. A similar programme in Scotland, the “Sleep at Home” initiative, reported comparable results, with wait times falling from nine months to five months over a two-year period.

What the Gap Means for Patients and Clinicians

For patients, the wait is not merely frustrating; it carries real health consequences. A 2023 study in Chest found that untreated severe OSA was associated with a 2.5-fold increase in incident hypertension over five years. The link with stroke is also well established, with a hazard ratio of roughly 1.8 in a large Taiwanese cohort. For drivers, the risk of a motor vehicle accident is two to three times higher than in the general population, a fact that the DVLA takes seriously—patients with excessive sleepiness are required to notify the agency. A 2022 analysis from the RAC Foundation estimated that sleep-related crashes cost the UK economy around £3 billion annually in medical costs, lost productivity, and property damage.

GPs are often left managing these patients with no clear escalation pathway. They can refer to a sleep centre, but once the referral is made, they have limited visibility into the wait time. Some prescribe stimulants such as modafinil off-label to manage daytime sleepiness, but this does not address the underlying airway obstruction. Modafinil can also have side effects, including headache, anxiety, and potential for dependence. A survey by the Royal College of General Practitioners found that 70% of GPs felt inadequately trained to manage OSA, and 55% reported that they had no access to local sleep services for advice.

Patient advocacy groups, including Sleep Apnoea UK and the British Lung Foundation, have called for ring-fenced funding for sleep services and national waiting-time targets. They argue that OSA is a treatable condition that, if left untreated, leads to costly complications. A 2021 report from the Office of Health Economics estimated that untreated OSA costs the NHS roughly £1.5 billion per year in cardiovascular disease, stroke, and accident-related admissions.

Clinicians also bear the burden. Respiratory physiologists report high burnout rates, and some sleep centres have closed their waiting lists entirely, accepting only urgent referrals. The result is a two-tier system: patients who can afford private care—at a cost of roughly £1,500–2,000 for diagnosis and setup—can bypass the queue, while those who cannot wait in limbo. This inequity is particularly stark given that OSA is more common in lower socioeconomic groups, where obesity rates are higher and access to private healthcare is limited.

Three Policy Levers That Could Close the Gap

First, expanding community-based setup, as piloted in Manchester, could reduce pressure on hospital beds and shorten waits. This would require investment in auto-CPAP devices and remote monitoring infrastructure, but the upfront cost may be offset by savings in follow-up visits. A health economics analysis from the pilot estimated a net saving of £120 per patient over two years. Scaling this model nationally could save the NHS tens of millions annually, while also improving patient experience.

Second, increasing training posts for respiratory physiologists is essential. The NHS Long Term Workforce Plan, published in 2023, committed to expanding the number of clinical scientist training places, but the target for respiratory physiology is not specified. Professional bodies have called for at least 50 new training posts per year for the next five years. In addition, creating a “sleep technician” role—a shorter training pathway focused on device setup and troubleshooting—could help bridge the gap. Some trusts have already piloted this, with promising results: a 2023 study from Sheffield showed that sleep technicians could reduce physiologist workload by 30% without compromising quality.

Third, adopting national key performance indicators (KPIs) for the time from diagnosis to treatment could drive accountability. Currently, no such target exists for OSA, unlike for cancer or cardiac surgery. A KPI of, say, 90 days for PAP setup would force trusts to redesign pathways and allocate resources. Device libraries—where patients can borrow a machine for a trial period—could also reduce upfront cost barriers and improve adherence. A pilot device library in Liverpool, launched in 2022, allowed patients to trial a CPAP machine for two weeks before committing to purchase. Of the 150 participants, 85% went on to purchase the device, and adherence rates at six months were 20% higher than in the standard pathway.

None of these levers is a silver bullet. The rising prevalence of OSA, driven by obesity and an ageing population, will continue to strain services. But the gap between what guidelines recommend and what patients experience is too wide to ignore. As one patient advocate put it: “We have a treatment that works. The problem is getting it to the people who need it.”

This article is for informational purposes only and does not constitute personalised medical advice. Readers should consult a healthcare professional for guidance specific to their condition.